Needham analyst Matt McGinley maintained a Buy rating on Trulieve Cannabis (OTC:TCNNF) on Tuesday, setting a price target of 60.5, which is approximately 39.70% above the present share price of $43.31.
McGinley expects Trulieve Cannabis to post earnings per share (EPS) of $0.04 for the first quarter of 2021.
The current consensus among 6 TipRanks analysts is for a Strong Buy rating of shares in Trulieve Cannabis, with an average price target of $49.31.
The analysts price targets range from a high of $60.5 to a low of $35.35.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $136.27 million and a net profit of $43.43 million. The company's market cap is $5.1 billion.
According to TipRanks.com, Needham analyst Matt McGinley is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 123.0% and a 88.57% success rate.
Trulieve Cannabis Corp. engages in the provision of medical cannabis products. The firm cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. Its products include smokable flower, inhalation, oral, sublingual, topical, inter-nasal, and concentrates. The company was founded on September 21, 2018 and is headquartered in Quincy, FL.